Madrid | January 28, 2026 — Corify Care, a cardiovascular MedTech innovator, announced a major advancement in cardiac electrophysiology with the publication of its Global Volumetric Mapping technology in Nature Communications Medicine. The technology represents the first system capable of mapping all four chambers of the heart simultaneously in a single beat, offering clinicians a real-time, whole-heart view of cardiac arrhythmias that overcomes long-standing limitations of chamber-by-chamber mapping approaches used in today’s electrophysiology (EP) labs.
Science Significance
From a scientific standpoint, Corify Care’s innovation marks a paradigm shift in arrhythmia characterization. Conventional cardiac mapping technologies analyze electrical activity one chamber at a time, forcing clinicians to infer arrhythmia behavior across unseen regions of the heart. Corify’s volumetric ECG imaging (ECGI) approach enables non-invasive, three-dimensional visualization of electrical propagation throughout the heart wall, septum, and across chambers. By delivering a single-beat, global map, the technology provides a complete physiological picture of arrhythmia dynamics, including deep intramural circuits that are often missed with existing tools, advancing the scientific understanding of complex atrial and ventricular arrhythmias.
Regulatory Significance
The announcement carries important regulatory and cGxP-adjacent implications for medical device innovation. The ACORYS® system is CE Marked, confirming compliance with European medical device quality and safety requirements, and is currently under review by the U.S. Food and Drug Administration (FDA). As a sophisticated diagnostic and procedural guidance system used in interventional cardiology, the platform must meet stringent quality management system (QMS), clinical evidence, and performance validation standards. Its progression through global regulatory pathways highlights the increasing regulatory focus on software-driven, data-intensive MedTech solutions used in high-risk clinical environments.
Business Significance
Advertisement
From a business perspective, Corify Care’s technology positions the company at the forefront of the next generation of EP lab infrastructure. By enabling faster decision-making, more targeted ablations, and reduced procedural complexity, whole-heart mapping has the potential to improve lab efficiency and scalability, key considerations for hospitals managing growing arrhythmia caseloads. Corify is actively pursuing integration with leading catheter navigation platforms, supporting a hybrid workflow that fits seamlessly into existing clinical ecosystems. Publication in a high-impact, peer-reviewed journal further strengthens the company’s clinical credibility and market differentiation as it advances toward U.S. commercialization.
Patients’ Significance
For patients, the implications are substantial. Cardiac arrhythmias such as atrial fibrillation and ventricular tachycardia often require complex ablation procedures, which can be lengthy and may involve repeat interventions if arrhythmogenic substrates are not fully identified. By offering physicians a complete, real-time view of arrhythmia pathways, Corify’s technology has the potential to support more precise ablation strategies, reduce unnecessary tissue damage, and shorten procedure times. Ultimately, this could translate into improved clinical outcomes, fewer repeat procedures, and enhanced patient safety, particularly for individuals with complex or treatment-resistant arrhythmias.
Policy Significance
At the policy level, the development aligns with broader healthcare priorities emphasizing innovation in cardiovascular care, patient safety, and data-driven clinical decision-making. As health systems worldwide confront the rising prevalence of cardiac arrhythmias, technologies that improve procedural efficiency and outcomes are increasingly relevant to value-based care models. Additionally, the regulatory review of advanced mapping systems underscores the need for clear, adaptive policy frameworks capable of evaluating complex, AI- and software-enabled medical devices while maintaining rigorous safety and performance standards.
Overall, Corify Care’s Global Volumetric Mapping technology represents a significant advancement in cardiac electrophysiology and regulated MedTech innovation. By delivering a true whole-heart, single-beat view of arrhythmias, the platform addresses critical blind spots in current mapping approaches and supports more confident, efficient clinical decision-making. For the cGxP.wire audience, the announcement highlights how scientific rigor, regulatory readiness, and patient-centered design are converging to shape the future of advanced cardiovascular medical devices.
Source: Corify Care press release
